<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622908</url>
  </required_header>
  <id_info>
    <org_study_id>373</org_study_id>
    <nct_id>NCT00622908</nct_id>
  </id_info>
  <brief_title>Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis</brief_title>
  <official_title>A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day
      (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of
      bacterial conjunctivitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)</measure>
    <time_frame>Visit 3 - day 8 or 9</time_frame>
    <description>Resolution of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eradication of Baseline Pathogens (Day 8 or 9)</measure>
    <time_frame>Visit 3 - Day 8 or day 9</time_frame>
    <description>Bacterial species eradication of baseline bacterial infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Resolution of Baseline Bacterial Conjunctivitis Day 4 (+/- 1 Day)</measure>
    <time_frame>Visit 2 - Day 4 (+/- 1 day)</time_frame>
    <description>The absence of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of Baseline Pathogens Day 4 (+/- 1 Day)</measure>
    <time_frame>Visit 2 - Day 4 (+/- 1 day)</time_frame>
    <description>Bacterial species eradication of baseline bacterial infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Bacterial Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>ISV-403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ISV-403 0.6%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of ISV-403</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-403</intervention_name>
    <description>0.6% TID, 5 days</description>
    <arm_group_label>ISV-403</arm_group_label>
    <other_name>besifloxacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle of ISV-403 TID, 5 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be at least one year of age.

          -  Must have signature of subject or legally authorized representative (if subject is
             under 18 years of age) on the informed Consent Form.

          -  Must have signature of subject on the Assent Form if subject is 6 to 17 years of age.

          -  Must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent
             conjunctival discharge (crusty or sticky eyelids) and redness in at least one eye. A
             minimum score of 1 should be present for discharge and a minimum score of 1 for either
             bulbar or palpebral conjunctival injection.

          -  Must have pinholed visual acuity equal to or better than 20/200 in both eyes. Age
             appropriate visual acuity testing was to be performed. Every effort was made to obtain
             a visual acuity measurement in children. If visual acuity was unobtainable in
             children, it was at the investigator's discretion to meet inclusion criteria.

          -  Must be willing to discontinue contact lens wear for the duration of the study.

          -  Must be willing to avoid disallowed medications during the study period.

          -  Must understand the scope of the study including completion of diary, be willing to
             follow instructions, and be able to make all required study visits.

          -  If a subject was a female of childbearing potential, she must utilize reliable
             contraceptive methods and have a negative pregnancy test.

        Exclusion Criteria:

          -  Any uncontrolled systemic disease or debilitating disease.

          -  Use of topical ophthalmic solutions including tear substitutes within two hours before
             and during the study.

          -  Use of any ophthalmic topical anti-inflammatory agents within 48 hours before and
             during the study.

          -  Subjects likely to require antimicrobial therapy with any active respiratory tract
             infection, urinary tract infection, skin/soft tissue infection, or otitis media.

          -  Pregnant or nursing females.

          -  Known hypersensitivity to SS734 or to any of the ingredients in the study medications.

          -  Known hypersensitivity to fluoroquinolones or to any of the ingredients in the study
             medications.

          -  Ocular surgery (including laser surgery) in either eye within the past six weeks.

          -  Subjects with suspected viral or allergic conjunctivitis (i.e., severe itching or
             acute follicular conjunctivitis), or any other disease conditions that could interfere
             with the efficacy and safety evaluations of the study medication.

          -  Subjects with suspected iritis (i.e., smaller pupil, pain, and photophobia in infected
             eye).

          -  History of recurrent corneal erosion syndrome, either idiopathic or secondary to
             previous corneal trauma or dry eye syndrome.

          -  Use of any antibiotic within 72 hours of enrollment.

          -  Any active ulcerative keratitis, specifically any epithelial loss greater than
             punctate keratitis

          -  Participation in an ophthalmic drug or device research study within the 30 days prior
             to entry in this study.

          -  Subjects who were immune compromised.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Comstock, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <results_first_submitted>June 29, 2009</results_first_submitted>
  <results_first_submitted_qc>August 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2009</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was started on 12/28/04 and last patient last visit was 6/7/05. This study took place at 35 centers in the US.</recruitment_details>
      <pre_assignment_details>270 subjects were enrolled, 269 were randomized(1 subject refused culture), 118 of which had bacteriologically confirmed acute bacterial conjunctivitis at baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ISV-403</title>
          <description>0.6% ISV-403</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of ISV-403</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137">Intent to treat population</participants>
                <participants group_id="P2" count="132">Intent to treat population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Termination by study sponser</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISV-403</title>
          <description>0.6% ISV-403</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of ISV-403</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="22.3"/>
                    <measurement group_id="B2" value="35.1" spread="22.4"/>
                    <measurement group_id="B3" value="34.2" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 to 19 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 to 59 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/=60 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)</title>
        <description>Resolution of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
        <time_frame>Visit 3 - day 8 or 9</time_frame>
        <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>0.6% ISV-403</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of ISV-403</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)</title>
          <description>Resolution of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
          <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eradication of Baseline Pathogens (Day 8 or 9)</title>
        <description>Bacterial species eradication of baseline bacterial infection</description>
        <time_frame>Visit 3 - Day 8 or day 9</time_frame>
        <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>0.6% ISV-403</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of ISV-403</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication of Baseline Pathogens (Day 8 or 9)</title>
          <description>Bacterial species eradication of baseline bacterial infection</description>
          <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Resolution of Baseline Bacterial Conjunctivitis Day 4 (+/- 1 Day)</title>
        <description>The absence of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
        <time_frame>Visit 2 - Day 4 (+/- 1 day)</time_frame>
        <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>0.6% ISV-403</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of ISV-403</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Resolution of Baseline Bacterial Conjunctivitis Day 4 (+/- 1 Day)</title>
          <description>The absence of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.</description>
          <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eradication of Baseline Pathogens Day 4 (+/- 1 Day)</title>
        <description>Bacterial species eradication of baseline bacterial infection</description>
        <time_frame>Visit 2 - Day 4 (+/- 1 day)</time_frame>
        <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-403</title>
            <description>0.6% ISV-403</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of ISV-403</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication of Baseline Pathogens Day 4 (+/- 1 Day)</title>
          <description>Bacterial species eradication of baseline bacterial infection</description>
          <population>Intent to treat population, culture confirmed. Missing values and discontinued patients imputed as failures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treated period was 5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISV-403</title>
          <description>0.6% ISV-403</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of ISV-403</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <description>Dehydration, not related to study medication</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E2" events="24" subjects_affected="8" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" events="28" subjects_affected="13" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E2" events="27" subjects_affected="16" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Eye Pruritis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has 45 days to review materials and provide comments back to the investigator.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Timothy Comstock</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(585) 338-6631</phone>
      <email>timothy.comstock@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

